Jonathan Rowe PhD, MS, MA

Dr. Jonathan D. Rowe, Ph.D, M.S., M.A., serves as the Head of Intellectual Property and Portfolio Strategy at Dignity Sciences Ltd. Dr. Rowe serves as Chief Operating Officer and Senior Vice President of Strategy & Clinical Innovation at Gene Express, Inc. Dr. Rowe served as the Head of Intellectual Property and Portfolio Strategy at Amarin Corporation plc. He has extensive experience in the development and commercialization of cardiovascular drugs and the strategic development of intellectual property. Prior to Gene Express, Dr. Rowe held numerous integral positions at Pfizer Inc. dating back to 1998. Most recently, he served as Senior Director of Worldwide Pharmaceutical Sciences in Pfizer's Global R&D Group. In this role, Dr. Rowe was accountable for aligning strategy, developing business metrics and delivering on process and performance improvements for the Pharmaceutical Sciences division.

This division consists of over 2700 colleagues, and was responsible for bringing newly discovered molecules to clinical trials, and product enhancements to existing products and candidates. Dr. Rowe's previous positions at Pfizer Inc. included: Director of Intellectual Property Strategy Management where he was responsible for developing and leading intellectual property lifecycle initiatives to increase the value and productivity of product franchises from candidates to post-marketing; and as Clinical Director of the Cardiovascular Risk Factors Group, Dr. Rowe designed, developed and managed phase IIIB and IV clinical studies, and lead the strategic medical input into the marketing and commercial development of Lipitor(R). Prior to Pfizer Inc., Dr. Rowe served as a scientific advisor for the lawfirm of Kaye,

Scholer where he provided scientific support for IP litigation group in the biotechnology and pharmaceutical industry. Dr. Rowe researched the expression of genes and their associated proteins involved in drug detoxification at Albert Einstein College of Medicine. Dr. Rowe has published a number of articles in peer-reviewed journals, has served as a consultant on the topics of Innovation and Strategy Implementation, and serves as an expert panel member for The Innovator, a publication supported by www.innovationtools.com and the Monitor Group's Innovation Practice. Dr. Rowe received PhD from the Department of Biochemistry at the Albert Einstein College of Medicine (AECOM) and holds MS with a focus on molecular biology (AECOM) and an MA in reproductive endocrinology from the State University of New York at Binghamton.